Literature DB >> 2930071

Buspirone, an anxiolytic drug that stimulates respiration.

S J Garner1, F L Eldridge, P G Wagner, R T Dowell.   

Abstract

The recently released drug buspirone is an anxiolytic agent that appears not to have the sedating effects of barbiturates and benzodiazepines, both known to have respiratory depressant effects. Because of its increasing clinical use, we desired to study the effects of buspirone on respiratory control. We therefore determined central neural respiratory responses, measured from phrenic nerve activity, after intravenous administration in paralyzed, vagotomized, and glomectomized cats whose end-tidal PCO2 and body temperature were kept constant. The responses were compared to the effects of the sedating tranquilizer diazepam. Buspirone had a dose-dependent stimulatory effect on respiratory output primarily through an increase of tidal activity but with an increase of frequency in some animals. Associated with this was a shift of the apneic threshold to a lower level of PCO2 without a change of slope or shape of the CO2 response curve. In contrast, diazepam led to a depression of respiration and a shift of the apneic threshold to a higher PCO2. The findings indicate that buspirone does not have the typical neural respiratory depressant actions of diazepam but instead stimulates respiration. Although the findings will need to be shown to apply to human beings, they suggest that buspirone may be a useful drug to treat anxiety in patients without causing undesirable respiratory depression.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2930071     DOI: 10.1164/ajrccm/139.4.946

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  11 in total

Review 1.  The use of psychotropics in the medically ill.

Authors:  M J Robinson; J L Levenson
Journal:  Curr Psychiatry Rep       Date:  2000-06       Impact factor: 5.285

2.  Serotonergic modulation of respiratory rhythmogenesis and central chemoreception.

Authors:  Matthew J Gdovin; Debora A Zamora; C R Marutha Ravindran; James C Leiter
Journal:  Ethn Dis       Date:  2010       Impact factor: 1.847

Review 3.  Management of dyspnea in patients with chronic obstructive pulmonary disease.

Authors:  Amy P Abernethy; Hope E Uronis; Jane L Wheeler; David C Currow
Journal:  Wien Med Wochenschr       Date:  2009-12

4.  8-OH-DPAT abolishes the pulmonary C-fiber-mediated apneic response to fentanyl largely via acting on 5HT1A receptors in the nucleus tractus solitarius.

Authors:  Jianguo Zhuang; Zhenxiong Zhang; Cancan Zhang; Fadi Xu
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2012-06-13       Impact factor: 3.619

5.  Effects of buspirone on posthypoxic ventilatory behavior in the C57BL/6J and A/J mouse strains.

Authors:  Motoo Yamauchi; Jesse Dostal; Hiroshi Kimura; Kingman P Strohl
Journal:  J Appl Physiol (1985)       Date:  2008-05-29

Review 6.  Anxiety in elderly patients. A comparison of azapirones and benzodiazepines.

Authors:  J R Steinberg
Journal:  Drugs Aging       Date:  1994-11       Impact factor: 3.923

7.  Buspirone decreases susceptibility to hypocapnic central sleep apnea in chronic SCI patients.

Authors:  Scott Maresh; Joel Prowting; Sarah Vaughan; Elizabeth Kruppe; Bander Alsabri; Hossein Yarandi; M Safwan Badr; Abdulghani Sankari
Journal:  J Appl Physiol (1985)       Date:  2020-08-20

Review 8.  Countermeasures for Preventing and Treating Opioid Overdose.

Authors:  Charles P France; Gerard P Ahern; Saadyah Averick; Alex Disney; Heather A Enright; Babak Esmaeli-Azad; Arianna Federico; Lisa R Gerak; Stephen M Husbands; Benedict Kolber; Edmond Y Lau; Victoria Lao; David R Maguire; Michael A Malfatti; Girardo Martinez; Brian P Mayer; Marco Pravetoni; Niaz Sahibzada; Phil Skolnick; Evan Y Snyder; Nestor Tomycz; Carlos A Valdez; Jim Zapf
Journal:  Clin Pharmacol Ther       Date:  2020-11-29       Impact factor: 6.875

Review 9.  Understanding and countering opioid-induced respiratory depression.

Authors:  Jordan T Bateman; Sandy E Saunders; Erica S Levitt
Journal:  Br J Pharmacol       Date:  2021-06-05       Impact factor: 8.739

Review 10.  Palliative management of refractory dyspnea in COPD.

Authors:  Hope E Uronis; David C Currow; Amy P Abernethy
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2006
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.